NEW YORK (360Dx) – Emosis, BioRap Technologies, and Rambam MedTech said today that they have entered into an exclusive license agreement to develop and commercialize a microparticle biomarker hypercoagulation kit for several indications.

The license is based on technology developed by researchers at the Rappaport Institute at the Technion-Israel Institute of Technology and Rambam Healthcare Campus, an academic hospital serving more than 2 million residents in northern Israel.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.